← All trials
NCT04858308
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 29, 2021
- Primary completion
- May 31, 2021
- Completion date
- Jan 31, 2022
- First posted
- Apr 26, 2021
- Last posted
- Apr 26, 2021
- Enrollment
- 554
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yooyoung Pharmaceutical Co.,Ltd.Lead sponsor
- Seoul National UniversityStudy chair
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.